aTyr Pharma

Today we announced a research study with Stanford Medicine to explore the role of our anti-neuropilin-2 (NRP2) antibodies in glioblastoma multiforme (GBM), the most common type of primary brain cancer. Dr. Michael Lim, Chair of the Department of Neurosurgery at Stanford Medicine, will serve as the principal investigator for the study, which aims to evaluate the NRP2 antibodies in combination with chemotherapy to evaluate their role in reversing immune evasion in GBM. This study presents an important opportunity to enhance our mechanistic understanding regarding the role of NRP2 in mediating immune suppression in an extremely aggressive cancer where there is a high unmet medical need. We look forward to potential findings from this research. Read more here: https://bit.ly/3A4735A #neuropilin2 #NRP2 #GlioblastomaMultiforme #GBM #cancer

We are pleased to announce that we have completed enrollment in the global pivotal Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The study enrolled 268 patients at 85 centers in 9 countries, exceeding target enrollment. Topline data from the study are expected in the third quarter of 2025. We are grateful to all of the patients and their caregivers, our principal investigators and their teams, our many advocacy partners and our partner Kyorin Pharmaceutical Co., Ltd., who helped make this accomplishment possible and bring us one step closer to potentially delivering a new treatment option to address the significant unmet need for pulmonary sarcoidosis patients. For more information, visit: https://bit.ly/3YeM1vc #efzofitimod #efzofit #sarcoidosis #pulmonarysarcoidosis

Today is #WorldSclerodermaDay! This is an important day to bring awareness to this chronic, progressive, autoimmune connective tissue disorder. aTyr is proud to recognize and understand that with #scleroderma, #EveryJourneyMatters, which is why we are working to develop #efzofitimod as a potential new treatment for those living with #SScILD, a form of #systemicsclerosis that affects the lungs. For more information, visit https://bit.ly/4cdr33P.

aTyr Pharma is now ATYR on Nasdaq! Effective at the market open today, aTyr’s common stock will trade on the Nasdaq Capital Market under the new symbol “ATYR.” No action is required by existing stockholders with respect to the ticker symbol change. Read more at: https://bit.ly/4c0CueI

Today we announced that we will be changing our Nasdaq stock ticker symbol from “LIFE” to “ATYR.” Effective at the market open on June 5, 2024, aTyr’s common stock will trade on the Nasdaq Capital Market under the new symbol “ATYR.” As we advance our lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study in pulmonary sarcoidosis and prepare for potential commercialization, the “ATYR” ticker symbol is a strong reflection of our corporate identity and serves to clarify and enhance our visibility across a broad range of stakeholders. No action is required by existing stockholders with respect to the ticker symbol change. Read more at: https://bit.ly/4c0CueI

June is #SclerodermaAwarenessMonth, which is an important opportunity to raise awareness and advocate for those living with all forms of #scleroderma. We are proud to support the #systemicsclerosis community by working to develop #efzofitimod as a potential new treatment for those living with #SScILD. Learn more at www.atyrpharma.com. #everyjourneymatters

We are looking forward to presenting new data on efzofitimod’s mechanism of action at the upcoming American Thoracic Society (ATS) 2024 International Conference. The poster presents findings further demonstrating that neuropilin-2 (NRP2) is an important new immune target in interstitial lung disease and that efzofitimod modulates myeloid cells to confer anti-inflammatory benefit. Join us at #ATS2024 or view the poster on our website once it has been presented. Read more at: https://bit.ly/4bdNkxU

Today we announced a second positive data and safety monitoring board (DSMB) review for efzofitimod in our ongoing Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. The DSMB recommended that the study could continue without any modifications after a second pre-planned, interim analysis. Current standard of care for patients with pulmonary sarcoidosis includes oral corticosteroids, which can incur significant side effects and toxicity. Efzofitimod has the potential to be a safe, non-steroidal treatment option for these patients, which is greatly needed. Read more here: https://bit.ly/4dBVcuP

Today we announced that Sanjay S. Shukla M.D., M.S., President and CEO of aTyr, will present at several upcoming investor conferences scheduled to take place in May and June 2024. Join us at the RBC Capital Markets Global Healthcare Conference on May 15th, the Piper Sandler Virtual Lung Investor Day on May 23rd and the Jefferies Global Healthcare Conference on June 5th. For more information, visit: https://bit.ly/3Uu9ODF

We released our First Quarter 2024 financial results and corporate update today. To read the full earnings press release, click here: https://bit.ly/3UHvhKA #aTyr #LIFE #earnings